Responses
Clinical/translational cancer immunotherapy
Original research
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Compose a Response to This Article
Other responses
No responses have been published for this article.
